 |
 |
PDC Biotech GmbH is a biotechnology company developing novel compounds for the treatment of preterm labour and primary dysmenorrhea. At the core of the company is our unique, proprietary series of prostaglandin F2α (FP) receptor antagonists. Preterm labour and primary dysmenorrhea are areas of significant unmet medical need. Excessive uterine contractility in both conditions is mediated by PGF2α.
A Phase I clinical trial of the company's lead compound is currently ongoing. This study is evaluating the safety, pharmacokinetics and effects of PDC31 on uterine contractility in non-pregnant women with primary dysmenorrhea.
More about us
Recent news:
November 15, 2010 PDC Biotech GmbH announces start of Phase l trial
|
|
